Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Manage your formulary budget
Find generic entry opportunities
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Mucopolysaccharide composition having a regulatory action on coagulation, medicament process for preparation and method of use|
|Abstract:||The invention pertains to a mucopolysaccharide fraction obtainable from heparin or from fractions including heparinic constituents of molecular weights from 2,000 to 50,000, which has a Yin-Wessler titer which is high relative to the USP titer. It contains components whose molecular weights are less than 10,000, particularly oligosaccharides in the area of 2,000-3,000, comprising from 8 to 12, notably 10 monosaccharide units, among which glucosamine units whose primary positions are sulphated. The last mentioned oligosaccharides include one N-acetyl-glucosamine unit per two units of 2-0-sulphate iduronic acid and per two N-sulphate-glucosamine units, the other saccharide units being of a different nature and including distinct substituents.|
|Inventor(s):||Lormeau; Jean C. (Maromme La Maine, FR), Choay; Jean (Paris, FR), Goulay, deceased; Jean (late of Oissel, FR), by Goulay, heir; Marie T. (St. Pierre de Varangeville, FR), by Goulay, heir; Marie A. (St. Pierre de Varangeville, FR), by Goulay, heir; Gerard (Saind Amand des Hautes Terres, FR)|
|Assignee:||Choay, S.A. (Paris, FR)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Formulation; Use; Process;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Bosnia and Herzegovina||97179||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.